Modern Pediatrics.Ukraine.2020.1(105):49-62; doi 10.15574/SP.2020.105.49
Okhotnikova О. M., Kvacheniuk О. H., Mellina K. V., Ponochevna О. V.
Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

For citation: Okhotnikova ОM, Kvacheniuk ОH, Mellina KV, Ponochevna ОV. (2020). Eosinophilic granulomatosis with polyangiitis: modern view on pathogenesis and treatment (literature review). Modern Pediatrics. Ukraine. 1(105): 49–62. doi 10.15574/SP.2020.105.49
Article received: Nov 30, 2019. Accepted for publication: Feb 06, 2020.

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg—Strauss syndrome is a rare systemic disease situated between primary small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCAs) and hypereosinophilic syndromes (HES). Clinical manifestations in EGPA tend to divide patients into two subsets of the disease, with a predominance of vasculitic or eosinophilic manifestations, and ANCA can differentiate between these two subsets. This subclassification contrasts ANCA-positive and ANCA-negative EGPA, but we have no insufficient understanding to use phenotype-tailored therapies. EGPA also remains a diagnostic problem because it can only be considered in the plane of allergic pathology for a long time. Asthma may be the primary or predominant manifestation for years, and the chronic corticosteroids requirement may mask other signs of the disease. Currently, immune dysregulation, genetic predisposition and clarify disease subcategorization are being actively studied, which can solve the problem of classification of EGPA.
All of which will allow us to opportune diagnosis the disease and use specially adapted therapies.
Key words: eosinophilic granulomatosis with polyangiitis, Churg-Strauss syndrome, hypereosinophilic syndromes, asthma.
No conflict of interest was declared by the authors.

REFERENCES

1. Beketova TV, Volkov MYu. (2016). The 2015 International guidelines for the diagnosis and treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology Science and Practice. 54(2): 129—137. https://doi.org/10.14412/1995-4484-2016-129-137

2. Azar N, Guillevin L, Huong Du LT, Herreman G, Meyrier A, Godeau P. (1989). Symptomatic urogenital manifestations of polyarteritis nodosa and Churg-Strauss angiitis: analysis of 8 of 165 patients. J Urol. 142(1): 136—138. https://doi.org/10.1016/S0022-5347(17)38686-X

3. Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. (2017). The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: a twenty-year US population-based study. Arthritis Rheumatol. 69(12): 2338—2350. https://doi.org/10.1002/art.40313; PMid:28881446 PMCid:PMC5711593

4. Bhamra K, Luqmani R. (2012). Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep. 14(6): 494—500. https://doi.org/10.1007/s11926-012-0291-1; PMid:22983618

5. Birck R et al. (2006). Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis. 47(1): 15—23. https://doi.org/10.1053/j.ajkd.2005.09.022; PMid:16377381

6. Choi YH, Im JG, Han BK, Kim JH, Lee KY, Myoung NH. (2000). Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest. 117(1): 117—124. https://doi.org/10.1378/chest.117.1.117; PMid:10631208

7. Churg A. (2001). Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol. 14(12): 1284—1293. https://doi.org/10.1038/modpathol.3880475; PMid:11743052

8. Churg J, Strauss L. (1951). Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 27(2): 277—301.

9. Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, Le Guern V et al. (2007). Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in fortyeight patients. Arthritis Rheum. 15;57(4): 686–693. https://doi.org/10.1002/art.22679; PMid:17471546

10. Comarmond C., Pagnoux C, Khellaf M, Cordier JF et al. (2013). Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 65(1): 270–281. https://doi.org/10.1002/art.37721; PMid:23044708.

11. Cordier JF, Cottin V, Guillevin L, Bel E, Bottero P, Dalhoff K et al. (2013). L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Presse Med. 42(4 Pt 2): 507–510. https://doi.org/10.1016/j.lpm.2013.02.308; PMid:23490637

12. Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R et al. (2016). Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 48(5): 1429–1441. https://doi.org/10.1183/13993003.00097-2016; PMid:27587545

13. Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. (2004). Long-term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 63(12): 1649–1654. https://doi.org/10.1136/ard.2003.015453; PMid:15547090 PMCid:PMC1754837

14. Dejaco C et al. (2015). Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One. 26;10(3): e0121737. https://doi.org/10.1371/journal.pone.0121737; PMid:25812008 PMCid:PMC4374913

15. Dennert RM, van Paassen P, Schalla S, Kuznetsova T, Alzand BS, Staessen JA et al. (2010). Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum. 62(2): 627–634. https://doi.org/10.1002/art.27263; PMid:20112390

16. Durel CA, Berthiller J, Caboni S, Jayne D, Ninet J, Hot A. (2016). Long-term follow-up of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken). 68(3): 374–387. https://doi.org/10.1002/acr.22686; PMid:26315340

17. Erzurum SC, Underwood GA, Hamilos DL, Waldron JA. (1989). Pleural effusion in Churg-Strauss syndrome. Chest. 95(6): 1357–1359. https://doi.org/10.1378/chest.95.6.1357; PMid:2721280

18. Exley AR et al. (1997). Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 40(2): 371–380. https://doi.org/10.1002/art.1780400222; PMid:9041949

19. Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A. (2018). Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag. 7;14: 2385–2396. https://doi.org/10.2147/TCRM.S159949; PMid:30573961 PMCid:PMC6292233

20. Finkielman JD et al. (2007). Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 147(9): 611–619. https://doi.org/10.7326/0003-4819-147-9-200711060-00005; PMid:17975183

21. Flossmann O et al. (2011). Longterm patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 70(3): 488-494. https://doi.org/10.1136/ard.2010.137778; PMid:21109517

22. Gaffey C, Chun B, Harvey JC, Manz HJ. (1986). Phenytoin-induced systemic granulomatous vasculitis. Arch. Pathol. Lab. Med. 110(2): 131–135.

23. Gioffredi A, Maritati F, Oliva E, Buzio C. (2014). Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol. 3;5: 549. https://doi.org/10.3389/fimmu.2014.00549; PMid:25404930 PMCid:PMC4217511

24. Grayson PC et al. (2015). Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 54(8): 1351–1359. https://doi.org/10.1093/rheumatology/keu427; PMid:25406357 PMCid:PMC4502335

25. Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V et al. (2015). Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 26(7): 545–553. https://doi.org/10.1016/j.ejim.2015.04.022; PMid:25971154

26. Guillevin L, Guittard T, Bletry O, Godeau P, Rosenthal P. (1987). Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung. 165(3): 165–172. https://doi.org/10.1007/BF02714432; PMid:3108593

27. Guillevin L, Lhote F, Gallais V et al. (1995). Gastrointestinal tract involvement in polyarteritis nodosa and Churg-Strauss syndrome. Ann Med Interne (Paris). 146(4): 260–267.

28. Guillevin L, Lhote F, Gayraud M et al. (1996). Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 75(1): 17–28. https://doi.org/10.1097/00005792-199601000-00003; PMid:8569467

29. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. (2011). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 90(1): 19–27. https://doi.org/10.1097/MD.0b013e318205a4c6; PMid:21200183

30. Harrold LR et al. (2005). Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol. 32(6): 1076–1080.

31. Hauser T, Mahr A, Metzler C et al. (2008). The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 63(8): 677–682. https://doi.org/10.1136/thx.2007.087825; PMid:18276721

32. Hazebroek MR, Kemna MJ, Schalla S, Sanders-van Wijk S, Gerretsen SC, Dennert R et al. (2015). Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol. 15;199: 170-179. https://doi.org/10.1016/j.ijcard.2015.06.087; PMid:26209947

33. Herlyn K et al. (2008). Stable incidence of systemic vasculitides in schleswig-holstein, Germany. Dtsch Arztebl Int. 105(19): 355–361. https://doi.org/10.3238/arztebl.2008.0355; PMid:19629246 PMCid:PMC2696872

34. Imai H, Nakamoto Y, Hirokawa M, Akihama T, Miura AB. (1989). Carbamazepine-induced granulomatous necrotising angiitis with acute renal failure. Nephron. 51(3): 405–408. https://doi.org/10.1159/000185332; PMid:2918954

35. Jachiet M, Samson M, Cottin V, Kahn JE, Le Guenno G, Bonniaud P et al. (2016). Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol. 68(9): 2274–2282. https://doi.org/10.1002/art.39663
PMid:26946346

36. Jakiela B, Sanak M, Szczeklik W, Sokolowska B, Plutecka H, Mastalerz L et al. (2011). Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol. 29;1(64): 23—34.

37. Jarzobski J, Ferry J, Wombolt D, Fitch DM, Egan JD. (1970). Vasculitis with allopurinol therapy. Am Heart J. 79(1): 116—21. https://doi.org/10.1016/0002-8703(70)90401-1

38. Jennette JC. (2013). Overview of the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clin Exp Nephrol. 17(5): 603—606. https://doi.org/10.1007/s10157-013-0869-6; PMid:24072416 PMCid:PMC4029362

39. Jennette JC, Falk RJ. (2014). Pathogenesis of antineutrophil cytoplasmic autoantibodymediated disease. Nat Rev Rheumatol. 10(8): 463—473. https://doi.org/10.1038/nrrheum.2014.103; PMid:25003769

40. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al. (1994). Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 37(2): 187—192. https://doi.org/10.1002/art.1780370206; PMid:8129773

41. Jennette JC, Falk RJ, Bacon PA et al. (2013). 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65(1): 1—11. https://doi.org/10.1002/art.37715; PMid:23045170.

42. Jennette JC, Xiao H, Falk R, Gasim AM. (2011). Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib Nephrol. 169: 211—220. https://doi.org/10.1159/000314776; PMid:21252521 PMCid:PMC5507587

43. Khoury P, Zagallo P, Talar-Williams C et al. (2012). Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy. 67(9): 1149—1156. https://doi.org/10.1111/j.1398-9995.2012.02873.x; PMid:22775568 PMCid:PMC3418460

44. Koike H, Sobue G. (2013). Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Nephrol. 17(5): 683—685. https://doi.org/10.1007/s10157-012-0767-3; PMid:23385777

45. Kung KL, Yee PK. (2015). Churg-Strauss syndrome from an orthopaedic perspective. Hong Kong Med J. 21: 565–568. https://doi.org/10.12809/hkmj144357; PMid:26634374

46. Kupczyk M, Kuna P. (2018). Benralizumab: an anti-IL-5 receptor alpha monoclonal antibody in the treatment of asthma. Immunotherapy. 10(5): 349–359. https://doi.org/10.2217/imt-2017-0161; PMid:29359607

47. Lanham JG, Elkon KB, Pusey CD, Hughes GR. (1984). Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 63(2): 65—81. https://doi.org/10.1097/00005792-198403000-00001; PMid:6366453

48. Leiferman KM, Peters MS. (2018). Eosinophil-related disease and the skin. J Allergy Clin Immunol Pract. 6(5): 1462—1482.e6. https://doi.org/10.1016/j.jaip.2018.06.002; PMid:29902530

49. Mahr A, Guillevin L, Poissonnet M, Ayme S. (2004). Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. ArthritisRheum. 51(1): 92—99. https://doi.org/10.1002/art.20077; PMid:14872461

50. Martin RM, Wilton LV, Mann RD. (1999). Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf. 8(3): 179—189. https://doi.org/10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.0.CO;2-K

51. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al. (1990). The American College of Rheumatology 1990 criteria for the classiifcation of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 33(8): 1094—1100. https://doi.org/10.1002/art.1780330806; PMid:2202307

52. Metzler C, Csernok E, Gross WL, Hellmich B. (2010). Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol. 28;1 (57): 24—30.

53. Metzler C, Lamprecht P, Hellmich B, Reuter M, Arlt AC, Gross WL. (2005). Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon α. Ann Rheum Dis. 64(8): 1242—1243. https://doi.org/10.1136/ard.2004.032664; PMid:16014692 PMCid:PMC1755617

54. Metzler C, Schnabel A, Gross WL, Hellmich B. (2008). A phase II study of interferon alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 26;3(49): 35—40.

55. Millet A et al. (2013). Antineutrophil cytoplasmic antibody-associated vasculitides. Is it time to split up the group? Ann Rheum Dis. 72(8): 1273—1279. https://doi.org/10.1136/annrheumdis-2013-203255; PMid:23606701

56. Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, Amudala N et al. (2016). Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 75(2): 396—401. https://doi.org/10.1136/annrheumdis-2014-206095; PMid:25467294

57. Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M et al. (2013). A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 72(6): 1011—1017. https://doi.org/10.1136/annrheumdis-2012-201531; PMid:22887848

58. Mouthon L, Khaled M, Cohen P, Guillevin L, Mouthon L, Subra JF. (2001). Systemic small sized vessel vasculitis after massive antigen inhalation. Ann Rheum Dis. 60(9): 903—904.

59. Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. (2016). Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: a report of 6 cases. Joint Bone Spine. 83(1): 81—84. https://doi.org/10.1016/j.jbspin.2015.04.016; PMid:26494587

60. Office of National Statistics, www.statistics.gov.uk

61. Pagnoux C, Groh M. (2016). Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Expert Rev Clin Immunol. 12(10): 1059—1067. https://doi.org/10.1080/1744666X.2016.1191352; PMid:27191665

62. Pagnoux C, Guillevin L. (2010). Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol. 22(1): 21—28. https://doi.org/10.1097/BOR.0b013e328333390b; PMid:19851111

63. Pagnoux C, Guilpain P, Guillevin L. (2007). Churg-Strauss syndrome. Curr Opin Rheumatol. 19(1): 25—32. https://doi.org/10.1097/BOR.0b013e3280119854; PMid:17143092

64. Park KE, Chipps DR, Benson EM. (1999). Necrotizing vasculitis secondary to propylthiouracil presenting as purpura fulminans. Br. J. Rheumatol. 38(8): 790—792. https://doi.org/10.1093/rheumatology/38.8.790; PMid:10501437

65. Pelа G et al. (2006). Cardiac involvement in the Churg-Strauss syndrome. Am. J. Cardiol. 15;97(10): 1519—1524. https://doi.org/10.1016/j.amjcard.2005.11.088; PMid:16679097

66. Polzer K, Karonitsch T, Neumann T, Eger G, Haberler C et al. (2008). Eotaxin-3 is involved in Churg-Strauss syndrome – a serum marker closely correlating with disease activity. Rheumatology (Oxford). 47(6): 804—808. https://doi.org/10.1093/rheumatology/ken033; PMid:18397958

67. Puechal X, Pagnoux C, Baron G, Quemeneur T, Neel A, Agard C et al. (2017). Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol. 69(11): 2175—2186. https://doi.org/10.1002/art.40205; PMid:28678392

68. Puechal X, Rivereau P, Vinchon F. (2008). Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med. 19(5): 364—366. https://doi.org/10.1016/j.ejim.2007.09.001; PMid:18549941

69. Ramentol-Sintas M, Martinez-Valle F, Solans-Laque R. (2012). Churg-Strauss Syndrome: an evolving paradigm. Autoimmun Rev. 12(2): 235—240. https://doi.org/10.1016/j.autrev.2012.07.009; PMid:22796280

70. Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D et al. (2008). Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 58(2): 586—594. https://doi.org/10.1002/art.23198; PMid:18240234

71. Rosenwasser L. (1999). Leukotriene modifiers: new drugs, old and new reactions. J. Allergy Clin. Immunol. 103;3(1): 374—375. https://doi.org/10.1016/S0091-6749(99)70459-8

72. Roufosse F, Weller PF. (2010). Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 126(1): 39—44. https://doi.org/10.1016/j.jaci.2010.04.011; PMid:20538328 PMCid:PMC2902584

73. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D et al. (2005). Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 1;143(9): 632–638. https://doi.org/10.7326/0003-4819-143-9-200511010-00006; PMid:16263885

74. Sada KE, Amano K, Uehara R, et al. (2014). Research Committee on Intractable Vasculitides, the Ministry of Health, Labour, Welfare of Japan. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol. 24(4): 640–644. https://doi.org/10.3109/14397595.2013.857582; PMid:24289197

75. Samson M, Puechal X, Devilliers H, Ribi C, Cohen P, Stern M et al. (2013). Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 43: 60—69. https://doi.org/10.1016/j.jaut.2013.03.003; PMid:23590801

76. Sanders JS et al. (2006). Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford). 45(6): 724—729. https://doi.org/10.1093/rheumatology/kei272; PMid:16399845

77. Santos YA, Silva BR, Lira PN et al. (2017). Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes. Respir Med Case Rep. 8;21: 1–6. https://doi.org/10.1016/j.rmcr.2017.03.006; PMid:28337408 PMCid:PMC5352719

78. Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME et al. (2010). Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 126(1): 45—49. https://doi.org/10.1016/j.jaci.2010.03.042; PMid:20639008 PMCid:PMC3400024

79. Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E et al. (2006). Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 47(5): 770—779. https://doi.org/10.1053/j.ajkd.2006.01.026; PMid:16632015

80. Smedema J et al. (2004). Cardiac involvement of Churg Strauss syndrome demonstrated by magnetic resonance imaging. Clin. Exp. Rheumatol. 22;6(36): 75—78.

81. Suppiah R et al. (2011). A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford). 50(5): 899—905. https://doi.org/10.1093/rheumatology/keq400; PMid:21156667

82. Szczeklik W et al. (2010). Pulmonary findings in Churg-Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol. 29(10): 1127—1134. https://doi.org/10.1007/s10067-010-1530-3; PMid:20623310

83. Tai P, Holt ME, Denny P, Gibbs AR, Williams BD, Spry CJ. (1984). Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome. Br Med J (Clin. Res. Ed). 18;289(6442): 400—402. https://doi.org/10.1136/bmj.289.6442.400; PMid:6432117 PMCid:PMC1442412

84. Terrier B, Bieche I, Maisonobe T, Laurendeau I, Rosenzwajg M et al. (2010). Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood. 25; 116(22): 4523—4531. https://doi.org/10.1182/blood-2010-02-267542; PMid:20729468

85. Thai LH et al. (2013). Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev. 13(3): 313—318. https://doi.org/10.1016/j.autrev.2013.11.003; PMid:24225075

86. Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M et al. (2017). Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract 5(6): 1556—1563. https://doi.org/10.1016/j.jaip.2017.07.027; PMid:28916432

87. Tian BP, Zhang GS, Lou J, Zhou HB, Cui W. (2018). Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. J Asthma. 55(9): 956—965. https://doi.org/10.1080/02770903.2017.1379534; PMid:29211545

88. Tomasson G et al. (2012). Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis — a meta-analysis. Rheumatology (Oxford). 51(1): 100—109. https://doi.org/10.1093/rheumatology/ker280; PMid:22039267 PMCid:PMC3276294

89. Vaglio A, Buzio C, Zwerina J. (2013). Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 68(3): 261—273. https://doi.org/10.1111/all.12088; PMid:23330816

90. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF et al. (2012). Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 130(3): 607—612.e9. https://doi.org/10.1016/j.jaci.2012.02.019; PMid:22460074 PMCid:PMC4091810

91. Varricchi G, Bagnasco D, Borriello F, Heffler E, Canonica GW. (2016). Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 16(2): 186—200. https://doi.org/10.1097/ACI.0000000000000251; PMid:26859368 PMCid:PMC4768650

92. Watts RA, Lane S, Scott DG. (2005). What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol. 19(2): 191—207. https://doi.org/10.1016/j.berh.2004.11.006; PMid:15857791

93. Wechsler ME, Akuthota P, Jayne D et al. (2017). Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 18;376(20): 1921—1932. https://doi.org/10.1056/NEJMoa1702079; PMid:28514601 PMCid:PMC5548295

94. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. (2009). Churg-Strauss syndrome in patients treated with omalizumab. Chest. 136(2): 507—518. https://doi.org/10.1378/chest.08-2990; PMid:19411292

95. Weller PF, Bubley GJ. (1994). The idiopathic hypereosinophilic syndrome. Blood. 15;83(10): 2759–2779. https://doi.org/10.1182/blood.V83.10.2759.2759; PMid:8180373

96. Wieczorek S, Hellmich B, Gross WL, Epplen JT. (2008). Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum. 58(1): 329—330. https://doi.org/10.1002/art.23209; PMid:18163478

97. Wieczorek S, Holle JU, Epplen JT. (2010). Recent progress in the genetics of Wegener's granulomatosis and Churg-Strauss syndrome. Curr Opin Rheumatol. 22(1): 8—14. https://doi.org/10.1097/BOR.0b013e3283331151; PMid:19864953

98. Worthy S et al. (1998). Churg Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. AJR. 170(2): 297—300. https://doi.org/10.2214/ajr.170.2.9456932; PMid:9456932

99. Zwerina J et al. (2011). Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford). 50(10): 1823—1827. https://doi.org/10.1093/rheumatology/keq445; PMid:21266446

100. Zwerina J et al. (2009). The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg-Strauss syndrome. Arthritis Rheum. 60(2): 626—627. https://doi.org/10.1002/art.24285; PMid:19180487

101.Zwerina J, Eger G, Englbrecht M, Manger B, Schett G. (2009). Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum. 39(2): 108—115. https://doi.org/10.1016/j.semarthrit.2008.05.004; PMid:18639318